Document is current
Any future updates will be listed below
-
Authors
Monzo, Luca
Kobayashi, Masatake
Ferreira, João Pedro
Lamiral, Zohra
Delles, Christian
Clark, Andrew L.
Edelmann, Frank
González, Arantxa
Heymans, Stephane
Pellicori, Pierpaolo
Petutschnigg, Johannes
Verdonschot, Job A. J.
Rossignol, Patrick
Cleland, John G. F.
Zannad, Faiez
Girerd, Nicolas
,
-
Funding
Funding for this research was provided by:
Seventh Framework Programme (305507, 305507)
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 23 January 2025
First Online: 8 March 2025
Declarations
:
: The study was approved by all relevant ethics committees and regulatory bodies. All participants provided written informed consent prior to study-specific procedures.
: There is no data of individual persons included in the manuscript.
: S.H. acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON Arena-PRIME, 2017-18, Double Dosis, 2020-B005; Furthermore, we acknowledge the support of FWO G091018N and FWO G0B5930N to S.H. SH provides independent scientific advice on early development in the field of heart failure for AstraZeneca, Ribocure, and CSL Behring, and its university receives research support from AstraZeneca and CSL Behring. F.Z. reports personal fees from Applied Therapeutics, Bayer, Boehringer, BMS, CVRx, Cardior, Cereno Pharmaceutical, Cellprothera, CEVA, Merck, Novartis, Novo Nordisk, Owkin, Pfizer and Servier, having stock options at G3 Pharmaceuticals and equities at Cereno Pharmaceutical, Cardiorenal and Eshmoun Clinical Research and being the founder of Cardiovascular Clinical Trialists. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens. All other authors have nothing to disclose.
